Alterity (ATHE) Up on Interim Data From Advance MSA Study

Zacks07-18

Shares of Alterity Therapeutics ATHE were up 7.8% on Jul 17 after the company announced positive interim data from the phase II ATH434-202 study evaluating its lead pipeline candidate ATH434 for ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2452026431?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/LQ_ww2eZjlMvbiXmaf.EDA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e","is_english":true,"pubTime":"2024-07-18 23:01","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2452026431","market":"us","top_or_hot":-1,"title":"Alterity (ATHE) Up on Interim Data From Advance MSA Study","media":"Zacks","content":"<div>\n<p>Shares of Alterity Therapeutics ATHE were up 7.8% on Jul 17 after the company announced positive interim data from the phase II ATH434-202 study evaluating its lead pipeline candidate ATH434 for ...</p>\n\n<a href=\"https://finance.yahoo.com/news/alterity-athe-interim-data-advance-150100589.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alterity (ATHE) Up on Interim Data From Advance MSA Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlterity (ATHE) Up on Interim Data From Advance MSA Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-18 23:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/alterity-athe-interim-data-advance-150100589.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Alterity Therapeutics ATHE were up 7.8% on Jul 17 after the company announced positive interim data from the phase II ATH434-202 study evaluating its lead pipeline candidate ATH434 for ...</p>\n\n<a href=\"https://finance.yahoo.com/news/alterity-athe-interim-data-advance-150100589.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1923622291.USD","symbol_name":"Natixis Thematics Safety R/A USD","start_time":0,"source_url":"https://finance.yahoo.com/news/alterity-athe-interim-data-advance-150100589.html","article_id":"2452026431","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/LQ_ww2eZjlMvbiXmaf.EDA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2452026431","pubTimestamp":1721314860,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Shares of Alterity Therapeutics ATHE were up 7.8% on Jul 17 after the company announced positive interim data from the phase II ATH434-202 study evaluating its lead pipeline candidate ATH434 for treating patients with multiple system atrophy , a rare neurodegenerative disease. The study enrolled 10 participants with advanced MSA.Per the press company, interim analysis results from the open-label ATH434-202 study included clinical and biomarker data from seven participants who were treated with ATH434 for six months and neuroimaging data from three participants who were treated with ATH434 for 12 months.In the past 60 days, estimates for Entrada Therapeutics’ 2024 loss per share have narrowed from 14 cents to 13 cents. Loss per share estimates for 2025 have narrowed from $3.44 to $3.21. Year to date, shares of TRDA have jumped 13.4%.In the past 60 days, estimates for Compugen’s 2024 earnings per share have improved from 2 cents to 5 cents, while loss per share estimates for 2025 have na","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1923622291.USD":"Natixis Thematics Safety R/A USD","ATH.AU":"ALTERITY THERAPEUTICS LTD","LU0728928796.USD":"abrdn SICAV I - GLOBAL SMALL&MID-CAP SDG HORIZONS EQUITY \"A\" (USD) ACC","BK4082":"医疗保健设备","BK4121":"生命科学工具和服务","ATHE":"Alterity Therapeutics Limited","CGEN":"Compugen医疗","BK4143":"办公服务与用品","TRDA":"Entrada Therapeutics, Inc.","LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","LU2125909759.SGD":"Natixis Thematics Safety H-R/A SGD","BK4139":"生物科技","LU0757428866.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","XAIR":"BEYOND AIR INC","MSA":"Mine Safety Appliances Co","LU2125909916.SGD":"Natixis Thematics Safety R/A SGD"},"translate_title":"Alterity(ATHE)基于高级MSA研究的中期数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATHE":1,"XAIR":1,"TRDA":1,"MSA":1,"CGEN":1,"ATH.AU":0.9},"content_text":"Shares of Alterity Therapeutics ATHE were up 7.8% on Jul 17 after the company announced positive interim data from the phase II ATH434-202 study evaluating its lead pipeline candidate ATH434 for treating patients with multiple system atrophy (MSA), a rare neurodegenerative disease. The study enrolled 10 participants with advanced MSA.\nPer the press company, interim analysis results from the open-label ATH434-202 study included clinical and biomarker data from seven participants who were treated with ATH434 for six months and neuroimaging data from three participants who were treated with ATH434 for 12 months.\nData from the same showed that 43% of the participants displayed improvement on the Unified MSA Rating Scale Part I (UMSARS1), indicating reduced disability in activities of daily living following six months of treatment. Also, 29% of the participants had stable or improved neurological symptoms at the same time.\nPatients who were treated with ATH434 had favorable clinical and biomarker outcomes, which underlined the potential of ATH434 to modify the course of MSA treatment.\nShares of Alterity have plunged 14.2% so far this year compared with the industry’s decline of 1%.\nPhase I studies conducted on ATH434 showed that the candidate is well tolerated and achieved brain levels that are comparable to efficacious levels seen in animal models of MSA.\nFinal 12-month data from the open-label ATH434-202 study is expected in the first half of 2025.\nAlterity is currently evaluating ATH434 across two separate mid-stage studies. Apart from the ATH434-202 study, which evaluates ATH434 in more advanced MSA, the phase II ATH434-201 study is evaluating ATH434 in early-stage MSA.\nAn oral candidate, ATH434, is designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration.\nATH434 has been granted orphan drug designation in treating MSA indications by the FDA and the European Medicines Agency.\nZacks Rank & Stocks to Consider\nAlterity currently carries a Zacks Rank #3 (Hold).\nSome top-ranked stocks in the biotech sector are Entrada Therapeutics, Inc. TRDA, Compugen Ltd. CGEN and Beyond Air, Inc. XAIR, each sporting a Zacks Rank #1 (Strong Buy) at present.You can see the complete list of today’s Zacks #1 Rank stocks here.\nIn the past 60 days, estimates for Entrada Therapeutics’ 2024 loss per share have narrowed from 14 cents to 13 cents. Loss per share estimates for 2025 have narrowed from $3.44 to $3.21. Year to date, shares of TRDA have jumped 13.4%.\nTRDA’s earnings beat estimates in two of the trailing four quarters and missed the same on the remaining two occasions, the average surprise being 42.18%.\nIn the past 60 days, estimates for Compugen’s 2024 earnings per share have improved from 2 cents to 5 cents, while loss per share estimates for 2025 have narrowed from 27 cents to 11 cents. Year to date, shares of CGEN have lost 6%.\nCGEN’s earnings beat estimates in three of the trailing four quarters and missed on the remaining occasion, the average surprise being 5.79%.\nIn the past 60 days, estimates for Beyond Air’s 2024 loss per share have narrowed from 44 cents to 35 cents. Loss per share estimates for 2025 have narrowed from $1.45 to $1.01. Year to date, shares of XAIR have plunged 71.4%.\nXAIR’s earnings beat estimates in three of the trailing four quarters while missing the same on the other occasion, the average surprise being 8.77%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nCompugen Ltd. (CGEN) : Free Stock Analysis Report\nPrana Biotechnology Ltd (ATHE) : Free Stock Analysis Report\nBeyond Air, Inc. (XAIR) : Free Stock Analysis Report\nEntrada Therapeutics, Inc. (TRDA) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2452026431"}